Sotorasib-d7 is a deuterium-labeled Sotorasib and a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. It irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state, leading to the regression of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Deuterium-labeled Sotorasib.
- First-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor.
- Irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state.
- Leads to the regression of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Can be used as a tracer.
- Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.